Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPT NASDAQ:IBRX NASDAQ:KRYS NASDAQ:NUVL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$14.13+1.8%$13.82$8.97▼$20.76$2.26B2.161.91 million shs904,541 shsIBRXImmunityBio$7.92+9.7%$7.73$1.95▼$12.43$8.30B0.0229.63 million shs19.03 million shsKRYSKrystal Biotech$302.68+1.1%$273.11$123.03▼$319.48$8.92B0.5295,539 shs181,915 shsNUVLNuvalent$104.95+2.8%$102.26$70.25▼$113.01$8.29B1.15556,761 shs425,575 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies0.00%+9.21%-1.84%-13.52%+55.43%IBRXImmunityBio0.00%-9.75%-2.96%-37.49%+185.38%KRYSKrystal Biotech0.00%+2.64%+9.88%+12.20%+139.46%NUVLNuvalent0.00%+2.22%-2.28%-2.70%+38.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$14.13+1.8%$13.82$8.97▼$20.76$2.26B2.161.91 million shs904,541 shsIBRXImmunityBio$7.92+9.7%$7.73$1.95▼$12.43$8.30B0.0229.63 million shs19.03 million shsKRYSKrystal Biotech$302.68+1.1%$273.11$123.03▼$319.48$8.92B0.5295,539 shs181,915 shsNUVLNuvalent$104.95+2.8%$102.26$70.25▼$113.01$8.29B1.15556,761 shs425,575 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies0.00%+9.21%-1.84%-13.52%+55.43%IBRXImmunityBio0.00%-9.75%-2.96%-37.49%+185.38%KRYSKrystal Biotech0.00%+2.64%+9.88%+12.20%+139.46%NUVLNuvalent0.00%+2.22%-2.28%-2.70%+38.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.63Moderate Buy$19.5738.51% UpsideIBRXImmunityBio 2.71Moderate Buy$14.2079.29% UpsideKRYSKrystal Biotech 2.83Moderate Buy$324.117.08% UpsideNUVLNuvalent 2.94Moderate Buy$140.2933.68% UpsideCurrent Analyst Ratings BreakdownLatest ADPT, KRYS, NUVL, and IBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$189.005/21/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$189.005/21/2026IBRXImmunityBio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.005/21/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/20/2026IBRXImmunityBio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.005/18/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.005/12/2026ADPTAdaptive Biotechnologies Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$21.00 ➝ $18.005/8/2026IBRXImmunityBio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$12.005/6/2026ADPTAdaptive Biotechnologies TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $21.005/6/2026ADPTAdaptive Biotechnologies JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$21.00 ➝ $19.005/6/2026ADPTAdaptive Biotechnologies GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$21.00(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$276.98M8.16N/AN/A$1.40 per share10.09IBRXImmunityBio$113.29M73.22N/AN/A($0.83) per share-9.54KRYSKrystal Biotech$389.13M22.93$7.37 per share41.08$43.31 per share6.99NUVLNuvalentN/AN/AN/AN/A$14.87 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$59.50M-$0.33N/AN/AN/A-16.82%-40.06%-16.64%8/4/2026 (Estimated)IBRXImmunityBio-$351.40M-$0.85N/AN/AN/A-606.15%N/A-59.53%8/4/2026 (Estimated)KRYSKrystal Biotech$204.83M$7.4840.4728.77N/A53.92%19.25%17.62%8/3/2026 (Estimated)NUVLNuvalent-$425.38M-$6.06N/AN/AN/AN/A-40.11%-35.43%8/6/2026 (Estimated)Latest ADPT, KRYS, NUVL, and IBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026IBRXImmunityBio-$0.08-$0.62-$0.54-$0.62$43.07 million$44.21 million5/7/2026Q1 2026NUVLNuvalent-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A5/5/2026Q1 2026ADPTAdaptive Biotechnologies-$0.16-$0.13+$0.03-$0.13$61.03 million$70.87 million5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A3.353.22IBRXImmunityBioN/A6.676.66KRYSKrystal BiotechN/A9.469.06NUVLNuvalentN/A16.1416.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%IBRXImmunityBio8.58%KRYSKrystal Biotech86.29%NUVLNuvalent97.26%Insider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies5.70%IBRXImmunityBio69.48%KRYSKrystal Biotech13.10%NUVLNuvalent5.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790160.04 million150.92 millionOptionableIBRXImmunityBio5901.05 billion319.65 millionOptionableKRYSKrystal Biotech21029.48 million25.62 millionOptionableNUVLNuvalent4079.00 million75.03 millionOptionableADPT, KRYS, NUVL, and IBRX HeadlinesRecent News About These CompaniesBernstein initiates coverage of Nuvalent (NUVL) with outperform recommendationMay 23 at 2:57 PM | msn.comNuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual MeetingMay 21, 2026 | prnewswire.comGuggenheim Sticks to Their Buy Rating for Nuvalent (NUVL)May 15, 2026 | theglobeandmail.comState of New Jersey Common Pension Fund D Sells 15,228 Shares of Nuvalent, Inc. $NUVLMay 11, 2026 | marketbeat.comUBS Group AG Acquires 185,932 Shares of Nuvalent, Inc. $NUVLMay 8, 2026 | marketbeat.comNuvalent (NASDAQ:NUVL) Announces Quarterly Earnings ResultsMay 7, 2026 | marketbeat.comNuvalent (NASDAQ:NUVL) CEO Sells $3,050,700.00 in StockMay 7, 2026 | insidertrades.comNuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial ResultsMay 7, 2026 | prnewswire.comComerica Bank Grows Holdings in Nuvalent, Inc. $NUVLMay 7, 2026 | marketbeat.comCanaccord Genuity Sticks to Their Buy Rating for Nuvalent (NUVL)May 6, 2026 | theglobeandmail.comJames Richard Porter Sells 30,000 Shares of Nuvalent (NASDAQ:NUVL) StockMay 6, 2026 | marketbeat.comNuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 6, 2026 | marketbeat.comVanguard Group Inc. Purchases 639,264 Shares of Nuvalent, Inc. $NUVLMay 5, 2026 | marketbeat.comInsider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 5,500 Shares of StockMay 1, 2026 | marketbeat.comNuvalent (NUVL) Submits NDA to FDA for Neladalkib in ALK-Positive NSCLCMay 1, 2026 | finance.yahoo.comNuvalent: A Precision Oncology Platform With Two Near-Term Shots On GoalApril 30, 2026 | seekingalpha.comGuardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ PlatformApril 30, 2026 | businesswire.comPictet Asset Management Holding SA Has $35.78 Million Holdings in Nuvalent, Inc. $NUVLApril 30, 2026 | marketbeat.comNuvalent (NUVL) Projected to Post Earnings on ThursdayApril 30, 2026 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Has $4.70 Million Position in Nuvalent, Inc. $NUVLApril 29, 2026 | marketbeat.comCanaccord Genuity Remains a Buy on Nuvalent (NUVL)April 24, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADPT, KRYS, NUVL, and IBRX Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$14.13 +0.25 (+1.80%) As of 04:00 PM EasternAdaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.ImmunityBio NASDAQ:IBRX$7.92 +0.70 (+9.70%) As of 04:00 PM EasternImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Krystal Biotech NASDAQ:KRYS$302.68 +3.23 (+1.08%) As of 04:00 PM EasternKrystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Nuvalent NASDAQ:NUVL$104.95 +2.83 (+2.77%) As of 04:00 PM EasternNuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AutoZone's Pullback Sets Up a Long-Term Buying Opportunity AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus Powerhouse Williams-Sonoma Heading to Fresh Highs in 2026 Quantum Stocks Just Got a Lifeline—Who Benefits Most? Why BJ’s Wholesale Club Stock Could Be Ready for a Rebound 5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade Rocket Companies Turns Around, But Mortgage Risk Remains After NVIDIA, Broadcom's Earnings Are Next—Here's What to Watch Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
